Vincent Ling

Vincent Ling is an executive with over 30 years of experience in industrial biotechnology.  He has initiated research projects, led science departments, and invested in drug-based technologies geared for therapeutic applications.  Within biotechnology he led research groups in stem cell biology, checkpoint inhibitor discovery, genomic mining, protein engineering, recombinant cell line generation, and biologics drug development.  For the past 15 years, Dr. Ling has focused on drug delivery technologies that incorporate formulation and material sciences to deliver small molecules, biologics, and cell / regenerative medicine assets.  Prior to his current role as Chief Business Officer at Morphocell Technologies, he held directorship roles in Pharmaceutical Sciences and Business Development in Takeda Pharmaceuticals.  He also served in leadership roles at Genetics Institute / Wyeth Pharmaceuticals, Adnexus, and Neurotech Pharmaceuticals.

Dr. Ling received his BA in UC Berkeley, and MS, PhD at University of Illinois.  Afterwards, he held a post-doctoral position at the Harvard Biological Laboratories as a NASA research fellow in space biology.

‍